Imagion Biosystems Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBX.AX research report →
Price Chart
About the company
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer.
- CEO
- Robert Romeo Proulx
- IPO
- 2017
- Employees
- 11
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on IBX.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.40M
- P/E
- -0.64
- PEG
- -0.01
- P/S
- 209.81
- P/B
- -1.68
- EV/EBITDA
- -1.72
- Div Yield
- 0.00%
- Gross Margin
- -2293.56%
- Op Margin
- -16189.90%
- Net Margin
- -16746.15%
- ROE
- 142.99%
- ROIC
- -1025.50%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-8,808-100.4%
- Op Income
- $-3,584,892
- Net Income
- $-4,309,456-108.5%
- EPS
- $-0.02+66.3%
- OCF Growth
- -218.2%
- FCF Growth
- -218.2%
- 52W High
- $0.06
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- -0.20
- RSI (14)
- 38
- Avg Volume
- 2.78M
No earnings-call transcripts are available for IBX.AX yet.
- Free Float
- 100.0%
- Shares Outstanding
- 539.94M
- Float Shares
- 539.73M
Our IBX.AX coverage
Recent articles, reports, and earnings notes.
No research on IBX.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IBX.AX report →Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
gurufocus.com · Jun 25
Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
gurufocus.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.